findmyKOL
Clinical trialNCT05873686RecruitingPhase 1Interventional

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

SponsorNuvectis Pharma, Inc.Enrollment140Advanced Solid TumorMesotheliomaNSCLC (Non-small Cell Lung Cancer)Non-Small Cell Squamous Lung CancerNon-small Cell Lung AdenocarcinomaRenal Cancer
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

  • Gerald Falchook, MD

    Sarah Cannon Cancer Institute, HealthOne Denver

    Principal Investigator
  • Udai Banerji, Prof

    Institute of Cancer Research, Royal Marsden NHS Foundation Trust

    Principal Investigator

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

15 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United Kingdom
  • Western General Hospital - Nhs Lothian

    Edinburgh, United Kingdom

    Completed
  • the Royal Marsden Nhs Foundation and Trust

    London, United Kingdom

    Completed
United States
  • Mayo Clinic

    Phoenix, Arizona, United States

    Recruiting
  • Uc San Diego Moores Cancer Center

    La Jolla, California, United States

    Recruiting
  • Sarah Cannon Research Institute at Healthone

    Denver, Colorado, United States

    Recruiting
  • Mayo Clinic

    Jacksonville, Florida, United States

    Recruiting
  • University of Chicago

    Chicago, Illinois, United States

    Recruiting
  • Mayo Clinic Rochester

    Rochester, Minnesota, United States

    Recruiting
  • Memorial Sloan Kettering Cancer Center

    New York, New York, United States

    Recruiting
  • Cleveland Clinic

    Cleveland, Ohio, United States

    Recruiting
  • Oregon Health and Science University

    Portland, Oregon, United States

    Recruiting
  • Next Oncology Houston

    Houston, Texas, United States

    Recruiting
  • the University of Texas Md Anderson Cancer Center

    Houston, Texas, United States

    Recruiting
  • Next Oncology Dallas

    Irving, Texas, United States

    Recruiting
  • Next Oncology Virginia

    Fairfax, Virginia, United States

    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
26 Oct 2023
Primary completion
31 Mar 2027
Completion
31 Jul 2027
Last update posted
9 Jul 2026
Registered enrollment
140
Registry id
NCT05873686

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.